ADME Study of [14C]-Jaktinib in Healthy Male Subjects

Healthy Adult Male Volunteers Clinical Trial

Official title:
Absorption, Distribution, Metabolism, and Excretion Study of [14C]-Jaktinib in Chinese Male Healthy Subjects(The Mass Balance and Biotransformation Study of [14C]-Jaktinib).

Status Completed

Clinical Trial Summary

This study was designed to evaluate the mass balance and biotransformation after single-dose of [14C]-Jaktinib orally in Chinese healthy male subjects.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Healthy Adult Male Volunteers

Clinical Trial Details

NCT number	NCT05150717
Study type	Interventional
Source	Suzhou Zelgen Biopharmaceuticals Co.,Ltd
Contact
Status	Completed
Phase	Phase 1
Start date	January 4, 2022
Completion date	January 30, 2022

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT04873063` - Evaluation of Systemic Bioavailability and Effects on 24-Hour Plasma Cortisol Profile of 6 mg Delivered Once Daily Versus 3 mg Delivered Twice Daily in Healthy Adult Male Volunteers	Phase 1
Completed	`NCT05059743` - ADME Study of [14C]- Larotinib in Healthy Male Subjects	Phase 1
Completed	`NCT04616742` - Study to Evaluate the Mass Babance and Biotransformation of [14C]SHR6390 in Healthy Adult Male Volunteers	Phase 1
Completed	`NCT04260373` - Study to Evaluate the Mass Balance and Biotransformation of [14C]SHR4640 in Chinese Healthy Adult Male Volunteers.	Phase 1
Active, not recruiting	`NCT05095337` - Study to Evaluate the Mass Balance and Biotransformation of [14C]SHR1459 in Healthy Adult Male Volunteers	Phase 1
Completed	`NCT05109078` - ADME Study of [14C]- Rongliflozin in Healthy Male Subjects	Phase 1